CHU Tours - Hôpital Trousseau

Chambray-lès-Tours 37170

2 studies enrolling now · 6 studies all time

What they study most

Carcinoma, Merkel Cell, Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis, Ulcerative Colitis

Studies at this site

• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) — Completed
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies — Stopped early
• Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200) — Completed